AML1-MTG8 antibody

Details for Product No. ABIN965546, Supplier: Log in to see
Immunohistochemistry (IHC)
Log in to see
Supplier Product No.
Log in to see

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Immunogen Polyclonal antibody produced in rabbits immunizing with a synthetic peptide corresponding to C-terminal residues of human AML1-MTG8(acute myelogenous leukemia 1 translocation 1 protein isoform MTG8c)
Purification Purified by antigen-specific affinity chromatography.
Background AML1-MTG8(acute myelogenous leukemia 1 translocation 1 protein isoform MTG8c) is a putative zinc finger transcription factor and oncoprotein. In acute myeloid leukemia, especially in the M2 subtype, the t(8,21)(q22,q22) translocation is one of the most frequent karyotypic abnormalities. The translocation produces a chimeric gene made up of the 5'-region of the RUNX1 gene fused to the 3'-region of this gene. The chimeric protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation. Several transcript variants encoding multiple isoforms have been found for this gene.
Application Notes ELISA, Western blotting: 1µg/ml for 2hrs.
Restrictions For Research Use only
Format Liquid
Buffer This antibody is stored in PBS, 50% glycerol
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage -20 °C
Background publications Liu, Shen, Huynh, Klisovic, Rush, Ford, Yu, Becknell, Li, Liu, Vukosavljevic, Whitman, Chang, Byrd, Perrotti, Plass, Marcucci: "Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia." in: Cancer research, Vol. 65, Issue 4, pp. 1277-84, 2005 (PubMed).

Lindberg, Olsson, Persson, Olsson: "The Leukemia-associated ETO homologues are differently expressed during hematopoietic differentiation." in: Experimental hematology, Vol. 33, Issue 2, pp. 189-98, 2005 (PubMed).

Lausen, Cho, Liu, Werner: "The nuclear receptor co-repressor (N-CoR) utilizes repression domains I and III for interaction and co-repression with ETO." in: The Journal of biological chemistry, Vol. 279, Issue 47, pp. 49281-8, 2004 (PubMed).

Zhang, Kalkum, Yamamura, Chait, Roeder: "E protein silencing by the leukemogenic AML1-ETO fusion protein." in: Science (New York, N.Y.), Vol. 305, Issue 5688, pp. 1286-9, 2004 (PubMed).

Chevallier, Corcoran, Lennon, Hyjek, Chadburn, Bardwell, Licht, Melnick: "ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein." in: Blood, Vol. 103, Issue 4, pp. 1454-63, 2004 (PubMed).

Lindberg, Olsson, Persson, Olsson: "Interactions between the leukaemia-associated ETO homologues of nuclear repressor proteins." in: European journal of haematology, Vol. 71, Issue 6, pp. 439-47, 2004 (PubMed).

McGhee, Bryan, Elliott, Grimes, Kazanjian, Davis, Meyers: "Gfi-1 attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase proteins, and represses transcription using a TSA-sensitive mechanism." in: Journal of cellular biochemistry, Vol. 89, Issue 5, pp. 1005-18, 2003 (PubMed).

Follows, Tagoh, Lefevre, Hodge, Morgan, Bonifer: "Epigenetic consequences of AML1-ETO action at the human c-FMS locus." in: The EMBO journal, Vol. 22, Issue 11, pp. 2798-809, 2003 (PubMed).

Tonks, Pearn, Tonks, Pearce, Hoy, Phillips, Fisher, Downing, Burnett, Darley: "The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells." in: Blood, Vol. 101, Issue 2, pp. 624-32, 2003 (PubMed).

Product cited in: Martinez, Drescher, Riehle, Cullmann, Vornlocher, Ganser, Heil, Nordheim, Krauter, Heidenreich: "The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells." in: BMC cancer, Vol. 4, pp. 44, 2004 (PubMed).